You are here

AQUALUNG THERAPEUTICS, CORP

Company Information
Address
450 OCEAN DR APT 1205
JUNO BEACH, FL 33408-2051
United States


http://www.aqualungtherapeutics.com

Information

UEI: mkdkz3zz99a2

# of Employees: 3


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    Amount: $809,000.00

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR applicat ...

    STTRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity

    Amount: $975,215.00

    ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focus ...

    STTRPhase II2023Department of Health and Human Services National Institutes of Health
  3. A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial

    Amount: $1,500,000.00

    ABSTRACT The serious unmet need to address the excessive mortality observed in patients with Acute Respiratory Distress Syndrome (ARDS) has been brought sharply into focus by the current COVID-19 pand ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  4. Targeting the P Selectin Pathway to Improve ARDS Survival

    Amount: $259,613.00

    ABSTRACT Acute respiratory distress syndrome (ARDS) is a critical illness with 30- 40% mortality and currently there are no FDA-approved therapies. Quell Pharma and Aqualung Therapeutics have develope ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  5. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    Amount: $259,613.00

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR applicat ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  6. Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity

    Amount: $269,233.00

    ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focus ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  7. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    Amount: $2,000,000.00

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR ...

    STTRPhase II2021Department of Health and Human Services National Institutes of Health
  8. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    Amount: $300,001.00

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  9. Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)

    Amount: $1,500,000.00

    Mortality rates in intensive care units (ICUs) are unacceptably high and are directly related to the duration of mechanical ventilation that is required to support patients with respiratory failure. F ...

    STTRPhase II2020Department of Health and Human Services National Institutes of Health
  10. Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP)

    Amount: $265,096.00

    ABSTRACT: Intrauterine infection and chorioamnionitis are common complications of pregnancy associated with significant maternal, perinatal, and long-term adverse outcomes. Adverse maternal outcomes i ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government